19h
Zacks Investment Research on MSNAMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis StudyAmgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...
Amgen has moved closer to a second indication for its B cell-depleting therapy Uplizna, acquired as part of its $27.8 billion takeover of Horizon Therapeutics last year, after positive results in ...
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...
Amgen has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating generalized myasthenia gravis, likely influencing its 14% price increase over the last ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
with a statistically significant change from baseline in MG-ADL score for UPLIZNA (-4.2) compared with placebo (-2.2) at Week 26 for the combined study population. Also Read: Amgen And Kyowa Kirin ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results